Illumina Delivers a Beat and a Raise in Q2
According to CEO Francis deSouza, the genetic life-sciences company is "firing on all cylinders."
Is It Too Late to Buy Idexx Laboratories?
This pet healthcare company is giving vets what they need, and its stock has been doing the same for investors.
Better Buy: Vertex vs. CRISPR
Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.
Is Moderna a Buy?
Moderna is riding high on the COVID-19 wave. Is it too late to get in?
Is Novavax a Buy?
After moving at less than warp speed, can this vaccine company catch up to the global opportunity?
3 Things About Regeneron That Smart Investors Know
The biotech's COVID-19 antibody cocktail made headlines last year, but there's a bigger story here.
3 Things About CRISPR Therapeutics That Smart Investors Know
The company is on track to be the first to market with a gene-editing therapy for blood disorders.
3 Things About Vertex Pharmaceuticals That Smart Investors Know
Can one multibillion-dollar blockbuster breakthrough lead to another?
3 Things About Fulgent Genetics That Smart Investors Know
Few companies had bigger tailwinds from COVID-19. What comes next could be even more exciting.
Is Illumina a Buy?
Illumina has gained almost 29% this year and could be headed higher.
3 Things About Invitae That Smart Investors Should Know
Could Invitae become the first $1 trillion market cap healthcare company?
Where Will ARK Genomic Revolution ETF Be in 5 Years?
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher?
Has Illumina Lost Its Shine?
Cathie Wood lost her conviction and dumped the stock. Can Illumina get back on track?
Is GoodRx the Prescription for Your Portfolio?
You're probably paying too much for your drugs. Fortunately, there's some help on the way.
What Does Life After COVID Look Like for Fulgent Genetics?
Fulgent rode on a wave of COVID revenue. What comes next could be pretty special.
Is Amazon Becoming a Healthcare Company?
Amazon has set its sights on the $4 trillion U.S. healthcare market.
Can Invitae Be the Winner-Take-Most in Genetic Testing?
Just like in poker, in some markets, the winner can take the whole pot. Can Invitae take home all the chips?
Is Intuitive Surgical the Tesla of Healthcare?
Tesla hopes to dominate the car market using robots and artificial intelligence. Can Intuitive Surgical do the same in the operating room?
Teladoc Health Is a Top ARK Holding. Should It Be One of Yours?
Investors shouldn't follow just anyone into a stock. Cathie Wood, however, might be a great guide.